New treatment strategies with erythropoietin (EPO) offer exciting opportunities to prevent the
onset and progression of neurodegenerative disorders that currently lack effective therapy …

Erythropoietin (Epo) has been thought to act exclusively on erythroid progenitor cells. The
identification of Epo receptor (EpoR) in non-haematopoietic cells and tissues including …

Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling
for neurodegenerative disorders may bring effective treatment for a number of difficult …

Background: Transient receptor potential (TRP) channels are a superfamily of ion channels
termed after the trp gene in Drosophila that are diverse in structure and control a wide range …

Background Recent studies revealed that erythropoietin (EPO) has tissue-protective effects
in the heart by increasing vascular endothelial growth factor (VEGF) expression and …

Carbamylated erythropoietin (cEpo), which is neuroprotective but lacks hematopoietic
activity, has been attracting rising concerns. However, the cellular and molecular …

Erythropoietin (Epo) is a pleiotropic cytokine, essential for erythropoiesis. Epo and its
receptor (Epo-R) are produced by several tissues and it is now admitted that Epo displays …

Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R)
injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin …

Background Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-
rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be …

Erythropoietin (EPO) has been shown to protect the heart against acute myocardial
infarction in pre-clinical studies, however, EPO failed to reduce infarct size in clinical trials …